Brief: Finch Therapeutics To Suspend Efforts To Initiate Phase 1 Trial Of FIN-211

Finch Therapeutics

01/09/2022 13:13

Sept 1 (Reuters) - Finch Therapeutics Group Inc  FNCH.O :
    * FINCH THERAPEUTICS GROUP INC - IT IS EVALUATING ITS
STRATEGY
ACROSS ITS ENTIRE PORTFOLIO
    * FINCH THERAPEUTICS GROUP INC - AS PART OF THIS ONGOING
REVIEW,
COMPANY WILL SUSPEND ITS EFFORTS TO INITIATE A PHASE 1 TRIAL OF
FIN-211
    * FINCH THERAPEUTICS - ESTIMATES IT WILL INCUR ABOUT $1.6
MILLION
IN COSTS CONSISTING OF ONE-TIME SEVERANCE PAYMENTS, OUTPLACEMENT
SERVICES,RELATED EXPENSES
    * FINCH THERAPEUTICS GROUP INC - EXPECTS TO RECORD A
SIGNIFICANT
PORTION OF THE CHARGES IN SECOND HALF OF 2022
    * FINCH THERAPEUTICS GROUP INC - RESTRUCTURING IS EXPECTED
TO BE
SUBSTANTIALLY COMPLETE BY END OF Q4 OF 2022

Source: (https://bit.ly/3q6T6va)
Further company coverage:  FNCH.O 

 ((Reuters.Briefs@thomsonreuters.com;))